Cited by 371Autism Spectrum Disorder ResearchBehavioral and Psychological StudiesChild Nutrition and Feeding Issues

Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial

Open access
Aman, Michael G., Mcdougle, Christopher J., Scahill, Lawrence, Handen, Benjamin, Arnold, L. Eugene, Johnson, Cynthia, Stigler, Kimberly A., Bearss, Karen +20 more·2009·Journal of the American Academy of Child & Adolescent Psychiatry

Abstract

Objective Many children with pervasive developmental disorders (PDDs) have serious, functionally impairing behavioral problems. We tested whether combined treatment (COMB) with risperidone and parent training (PT) in behavior management is superior to medication alone (MED) in improving severe behavioral problems in children with PDDs.Method This 24-week, three-site, randomized, parallel-groups clinical trial enrolled 124 children, aged 4 through 13 years, with PDDs, accompanied by frequent tantrums, self-injury, and aggression. The children were randomized 3:2 to COMB (n = 75) or MED (n = 49). The participants received risperidone monotherapy from 0.5 to 3.5 mg/day (with switch to aripiprazole if risperidone was ineffective). Parents in the COMB group (n = 75; 60.5%) received a mean of 10.9 PT sessions. The primary measure of compliance was the Home Situations Questionnaire (HSQ) score.Results Primary: intent-to-treat random effects regression showed that COMB was superior to MED on HSQ (p = .006) [effect size at week 24 (d) = 0.34]. The HSQ score declined from 4.31 (± 1.67) to 1.23 (± 1.36) for COMB compared with 4.16 (± 1.47) to 1.68 (± 1.36) for MED. Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, COMB showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04). Final risperidone mean dose for MED was 2.26 mg/day (0.071 mg/kg), compared with 1.98 mg/day for COMB (0.066 mg/kg) (p = .04).Conclusions Medication plus PT resulted in greater reduction of serious maladaptive behavior than MED in children with PDDs, with a lower risperidone dose.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/chi.0b013e3181bfd669

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a risperidone-plus-parent-training trial, the combined group showed less aggression and larger hyperactivity decreases than the medication-only group.

    “Results indicated that children who received parent training in addition to pharmacological treatment (i.e., risperidone) had lower rates of aggression and greater reductions in hyperactivity as compared to children who only received medication [63].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 51 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. [12]Scahill L Aman MG McDougle CJ Arnold LE McCracken JT Handen B Johnson C Dziura J Butter E Sukhodolsky D Swiezy N Mulick J Stigler K Bearss K Ritz L Wagner A Vitiello B Testing the combined effects of medication and behavioral intervention in children with pervasive developmental disorders J Autism Dev Disord 2009 39 720 729 19096921 PMC4807607
  2. [35]Barkley RA Edwards GH Robin AL Defiant Teens: A Clinician’s Manual for Assessment and Intervention New York Guilford Press 1999 196 198
  3. [41]Arnold LE Aman MG Martin A Collier-Crespin A Vitiello B Tierney E Bell-Bradshaw F Freeman BJ Gates-Ulanet P McCracken JT McDougle CJ McGough JJ Posey DJ Scahill L Swiezy NB Ritz L Volkmar FR Assessment in autism multisite randomized clinical trials (RCTs) J Autism Dev Disord 2000 30 99 111 10832774

Cited by

Sorted by citations

Authors
Aman, M. G., Mcdougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Stigler, K. A., Bearss, K., Butter, E., Swiezy, N. B., Sukhodolsky, D. D., Ramadan, Y., Pozdol, S. L., Nikolov, R., Lecavalier, L., Kohn, A. E., Koenig, K., Hollway, J. A., Korzekwa, P., Gavaletz, A., Mulick, J. A., Hall, K. L., Dziura, J., Ritz, L., Trollinger, S., Yu, S., Vitiello, B., & Wagner, A.
Affiliations
University of Pittsburgh (US)
Corresponding author
Aman, Michael G.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2009-12
Volume
48
Issue
12
Pages
1143-1154
ISSN
0890-8567 (ISSN-L)
OpenAlex
W2113512187
Cited by
371
References
51
Citations by year
2026: 6 · 2025: 29 · 2024: 12 · 2023: 12 · 2022: 19 · 2021: 31 · 2020: 22 · 2019: 13 · 2018: 53 · 2017: 19 · 2016: 21 · 2015: 23 · 2014: 21 · 2013: 30 · 2012: 30
FWCI
9.68
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • U.S. Public Health Service (ULRR025761)
  • National Institute of Mental Health (U10MH066768, U10MH066764, U10MH66766, U10MH066766, U 10MH66764, U10MH66768)
  • National Center for Research Resources (UL1RR025755, UL1RR024139)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
Keywords
pervasive developmental disorders, autism spectrum disorder, risperidone, parent training, behavior management, combined psychotherapy and pharmacotherapy, tantrums, self-harm, aggression, irritability, stereotypy, hyperactivity, aripiprazole, Aberrant Behavior Checklist, medication adherence, antipsychotic adverse effects
MeSH terms
Adolescent, Behavior Therapy, Child, Child Behavior Disorders, Child Development Disorders, Pervasive, Child, Preschool, Combined Modality Therapy, Dose-Response Relationship, Drug, Double-Blind Method, Education, Female, Humans, Male, Personality Assessment, Psychometrics, Antipsychotic Agents, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review